All right, we're going to get started. Thank you, everyone, for joining us for our inaugural UBS Global Biopharma Conference. My name is Joon Lee, one of the Biotech Analyst at UBS. For this session, we have Emil Kakkis, CEO of Ultragenyx, and CFO of Ultragenyx as well. Thank you. Emil, thanks for spending time with us. For the audience who may be new to the story, could you spend a few minutes describing the focus of the company and the recent updates, and why investors should pay attention to Ultragenyx now?
Thanks, Joon. Thanks for having us, and Howard and the whole Ultragenyx team's happy to be here. Ultragenyx is a company that's been on the public markets since 2014. We're a rare and ultrarare company with six approved products in those 12 years on the market, heading toward $1 billion in revenue next year, and we expect to be profitable next year, meaningful profitability achieved. We've been working in a wide variety of types of drugs, gene therapies, biologics like antibodies or enzymes, and small molecules as well. We're agnostic as to mode and focusing on the best possible treatment strategy. We had two misses this year that have been of challenge for the stock, including osteogenesis imperfecta, setrusumab program, as well as in the Angelman program. Between the two, the OI setrusumab program, we think, has great data that we're going to continue to pursue.
We can talk more about that at some point. The Angelman program, we have to set aside at this point. Because of that, we've implemented important cost-cutting, approximately 20% of our staff, and reduced R&D spend by 50%. I'm sure Howard can talk more about what we did, but the point where the meaningful cost reductions have put us on path to be profitable, full-year profitability next year, and put us in charge of our future. In addition, we sold two PRVs, which added about $350 million to the balance sheet, giving us more than $700 million cash. We are a balance sheet that's full, and we should be adding commercial cash over the coming year. So we're in a very good situation from the standpoint of profitability, but we did have two big catalyst misses put us where we are today.
We think we're going to turn that corner and move forward with the continued growth of our base business, plus the two gene therapy launches, which are doing well, and the continued pipeline focus on a narrower, tighter footprint of high-value programs, which includes setrusumab for OI, as well as our OTC program and an early-stage program. We're encouraged by where we're at, but we certainly have had two hits that have put us in a more difficult place. I'm confident in our future and our ability to be profitable and generate meaningful R&D value as well as commercial value going forward.
As Emil said, you've undertaken some really difficult but major reductions in the goal towards profitability. What are some pushes and pulls into your profitability assumptions? Once you achieve that profitability in 2027, how sustainable is that going forward?
Howard, do you want to answer that one? Since it's right up your alley.
Yes. We project profitability in 2027, and we've said we intend to sustain it. The assumptions that get us there, we have a base business of four programs that's been growing north of 20% since we've gone commercial. Then we have the two gene therapy launches that we're in the process of now, and I think we'll probably come back to some more detail on those. That gives you a growth rate on the top line where we can control our spend on R&D and SG&A. We gave some guidance on that on our last call. We will keep R&D next year under $350 million, and we'll keep SG&A under $375 million. Those facts get us to profitability. Importantly, as Emil mentioned, we now have the balance sheet strength to not need to raise to get to profitability. That's a pretty big corner to turn as a biotech to be able to say all of that in one year's time.
What proportion of the remaining headcount is focused on R&D versus SG&A?
You want to put that out?
Yeah, I do not know that we have guided directly to that. I think most of our costs, as in most companies, are people-based, a large percentage of them. We think, look, ultimately what we think is that the R&D that we have guided to can support the commercial programs, because there is still some R&D that goes on there, plus a very focused base of spend on R&D and the UX143 program and UX016 and the DTX301 programs. That is really the core of it. Our SG&A is meant to support the six programs we have on market globally.
Does the R&D spend take into account the potential new trial of setrusumab in osteogenesis imperfecta, which we will get into in a little bit?
Yeah, it absolutely does.
It does. All right.
Yeah, we do not have to change our guidance at all for that.
How much of the new launches need to be contributing to 2027 revenue to maintain your profitable guidance and sustainability of that profitability?
Yeah, with new launches, we don't tend to give that guidance for a little while, just to see how the uptake and whatnot. But if you look at the trends from our four current programs and apply sort of a normal growth rate to that, it's not a very big burden of add that you'd need from the two gene therapies.
And before we move on to the two recent launches, congratulations on GENGLYCOS and FAYUVI. From the existing commercial base of drugs, what do you expect in terms of growth of your core franchise, including Crysvita and Mepsevii and Dojolvi?
Yeah, so again, we haven't guided to that.
Yeah.
But historically, we've grown north of 20%. Last year was our slowest growing year, and it was 20%.
Got it.
It has been four or five, six years now, I think, of 20% growth. We have been very good. That growth is based on several things. One is, of course, the population growing, but I think we are adding new territories, including, for example, Japan, which had Evkeeza growth the year before. This year is launching Dojolvi. We have added Middle East. Middle East and Dojolvi is doing extremely well. A lot of patients in the Middle East being added through named patient, and now we have actually filed the follow-up there. As we build the territory, we are continuing to grow. So within established areas, the growth may be slower, but with the added territories, I think that is really continued to improve and maintain that growth rate, which has, I think, been exceptional performance by the commercial team, the entire team working to do that.
That global franchise now is set up to be able to take on two new products in the same inborn error space and to be able to launch. So we can leverage that investment now and put new products in it, and that is really what is going to be special about our ability to grow revenue and gain leverage commercially.
Crysvita, of the base business, Crysvita is a very important drug, doing about $5 million-$520 million per year. The composition of matter patent is up for, I guess, expiration in 2032-ish. What is your life cycle management strategy, and when do you need to start planning for that?
Kyowa Kirin and ourselves have been talking about it for a while. The first thing I would say about rare, ultrarare disease biologics is they do not really have loss of exclusivity and a decline in revenue like some other product areas. A lot of those programs maintain themselves, but we still have to plan for it, and we have to protect for it. I would not look at that as a precipitous cliff as it can be for other disease areas, partly for how they are commercialized through specialty pharmacies and individual contracts. So, with regard to LOE planning, Kyowa Kirin has done some work. We have done some work on next-gen versions of Crysvita. They already started in the clinic with our agreement. We have a non-compete with them, and so the plan is to collaborate on how we do these things. They have a couple molecules.
We have a molecule as well. We will come up with our plan to put in play and be able to launch next-gen version. The goal of the next-gen version would be to have some improvement, not just a version, but a version that has real property improvement. It is a challenge to make it more better because actually Crysvita is like a second-generation product out the gate, right? It is fully bioavailable subcutaneously, and it has no anti-drug antibody or hypersensitivity reaction.
Yeah.
It is a very clean profile. It is a very good drug. So we want to make it better while keeping those properties of an excellent drug. It is possible. We look to maybe improve potency to some degree, and we look at maybe extending the time. These are factors we would want to have a product that really was better. We are going to work together with Kirin on that problem. So we expect by the time LOE is happening, we already will have next-gen version of Crysvita.
Looking forward to that. I know you mentioned a couple of misses in recent times, but overall, your hit rates are pretty high, and you have two approvals people do not talk about as much. Overall, you have a pretty high hit rate because you are targeting diseases with well-known targets or drivers of diseases, and your FAYUVI and GENGLYCOS are examples of that. For both, what are the launch looking like so far, and how many patients have you identified that may be ready to be dosed and all that stuff?
So far, both products are doing well, and we are pleased with what we are seeing in launch. We will not put out specific numbers until we get to early in January. We will put out how many qualified treatment centers there are, how many start forms we have, and what the revenue was at the end of this year. But so far, things are going well, and we are encouraged by what we are seeing. I think FAYUVI is more urgent, and so it has certainly been more immediate and rapid interest because parents are rapidly interested, not just the U.S., but globally interested in getting treated. So that has been a sign I expected, but not everyone did. But I know the Sanfilippo community really well, and I was pretty sure their parents would be calling us or calling their doctors and driving to get treated.
Both are doing well from the standpoint of the number of patients out there. In Sanfilippo, it is around 3,000- 5,000 in the commercially accessible world, and for the other program, it is maybe around 6,000. About a fourth of them, right, are expected to be U.S. Within the Sanfilippo population, there may be some patients that are, let us say, bedridden at the end of life because they spend 5-1 0 years at the end of their lives. That state probably not within the label, which says preserve neurodevelopmental function.
Yeah.
That is not specific in the label, but I would expect those patients not to be. We certainly are aware of something on the order of 300 or 400 U.S. patients that are potentially treatable. And for GSD1A, it is on the order of 1,600, a couple thousand, depending on which way you look at it, are available. We would expect GSD1 to take a little more time. It is urgent, but not quite as crisis urgent as FAYUVI is. But we expect it is continuing to build, and we expect both programs to do well.
When would you be in a position to share things like start forms, scheduled infusions, and more concrete metrics of the launch?
We will be doing that in January.
Okay.
We will normally do that at the beginning of the year at a competitor conference.
Yes, I am aware.
We will not be putting out forecasts for the new products until we have about six quarters of experience. That has been our standard we set from all of our launches. We wait six quarters to get a feel for it. For gene therapy particularly, I think it is important too. We will be able to give you start forms, as well as reimbursed patients and revenue at that time. And we'll probably provide overall numbers for the coming year, which we have in the past, but we won't provide specific forecasts for those two new products. But we will provide them for the other programs.
That's fair enough. I know you've invested heavily in the manufacturing capacity of AAVs in the Massachusetts area. Tell us a little bit about that and what that implies. How many patients can you dose with the capacity that you have?
Well, in our view, if you're going to be in the AAV space, you really should try to invest in manufacturing capacity because it's a relatively high-cost, high-complexity situation, and I think it's far more cost-effective and more adaptable to manage yourself. So we have done that. We do have a partner for the FAYUVI drug substance in Andelyn, and we do the fill finish and the manufacturing for GENGLYCOS. And we would expect to be putting other gene therapy programs in that plant. I can't tell you the specific in how many patients we can treat out of the plant, because it really depends on which product and how many runs we run. The plant is operating one of the suites right now.
We have a second suite that's there that's not outfitted, but gives us capacity to increase. If we were using up the capacity, we could implement and outfit the second suite. It's already built. It's there. We could expand capacity without having to do another plant, right? We designed it that way, and we'd set it up to run one and then add the other. There is some cost to it, but it's not like building another plant. I think we've been pretty smart about how to do it the right way. Plant now, fully inspected and approved for producing both the products.
Excellent. Now, let's get into pipeline. Setrusumab for osteogenesis imperfecta. Looks like there's real signal based on the post hoc data. How much of that was pre-specified, or how much of that was just trying to do post-mortem and finding a signal?
Yeah, so if you look at the bone mineral density data, that, which hit a p-value of 0.001, was about one Z-score increase in bone mineral density, which is about a 30% increase in the young patients. That's a profound effect. So that's very statistically significant, pre hoc, post hoc, any way you want to do it. But it was a very profound effect. And that's what this drug is doing for these patients, dramatic improvement in bone mineral density. It also was successful head-to-head against both bisphosphonates in the other second study.
Yeah. Shocking.
It beat both. So, it is clearly better than what everyone is using routinely now for that effect in the BMD. That is all without any post hoc analysis. Those were the original analyses. We also found among the tertiary endpoints in the Orbit study, which was the placebo control, there were two different pain endpoints and two different physical functioning. Most of those were statistically significant, nominally significant, or a strong trend in pain and physical functioning as well. Those were tertiary, because usually those are hard to hit, but we actually hit them in tertiary. The thing we missed in the study was the fracture AFR. The fracture AFR, we missed in Orbit because the fracture rate was just too low. We had an entry criterion of at least one, and we stratified by above or below three. What we ended up with is an average of around 0.55, and the median in the placebo group was zero. So, this unfortunately left us not a lot of room to gain. What we announced at the post hoc was looking at the strata I just mentioned, above and below three.
If you look at the above three group in those patients, you see a meaningful effect. If you look at that study and you look at the other study, the Cosmic study, in the high fracture patients, you see a meaningful 40%-60% reduction in fractures, which is kind of what we were expecting to see in the study from the beginning. Our biggest problem was we did not enroll in Orbit enough high fracture patients. The other feature, which was true in the Cosmic study, is that the bones that were not long bones improved very dramatically. Clinical fractures of the vertebral column were reduced 94%. Went from 18 fractures in one group to one in the other.
Yeah.
Treated group.
Yeah.
The vertebral column is extremely important in OI. It is why patients end up with these collapsed spines and in wheelchairs, right? It is life-changing. That was a very strong effect, and the BMD effect on the spine is why that is happening. The long bones were not as well affected, but a lot of those patients have bent long bones, and they already have metal rods in them, right? So they are kind of structurally unsound. The patients were feeling better, and we think were just running around there and having more of those effects.
Yeah.
These are complexities. Sometimes you learn about this in the middle of a trial in OI, and we have learned some things from that. I think the fundamental truth is they have extremely low BMD. We have a dramatic effect on BMD, even head-to-head against active. That effect will improve fractures, particularly bones that are able to gain bone mineral density quickly, and that there is a pain physical functioning effect that is important to patients. So this is a drug that really does work in these patients, and it is worth fighting for. We are talking to the FDA about what that means, and we have said that there is some prospective data may be required. We are working through what that means. What I want to say is we are committed to figuring out one way or another.
We have built into our plan as if we are running another trial, and we are continuing to have our discussions. We have had a couple meetings with the FDA, but these processes take time. They are not instant. It is not something that gets solved in one meeting. It takes some time to work through a new situation. We as a company have done that multiple times. We have been involved in a lot of regulatory discussions. The FAYUVI approval was an example of one of a couple years of discussions on biomarker endpoints. We included the whole industry in that discussion, you may remember, in the battle over a biomarker. But in the end, FDA did agree, and we got them there, but it did take a little time.
Just a lot to unpack there. Number one, again, remind me, the three or more baseline fracture rate analysis, was that a pre-specified or no?
We pre-specified the strata of above and below three for randomization.
Okay.
Okay? So that strata was known to us.
Got it.
That it would matter.
Yes.
But we didn't.
And it mattered.
Specify the subset for the statistical analysis post hoc.
Got it. Understood. Now there are different subtypes within OI, type 1, 3, 4, I believe. One of them is just both alleles are mutant, and one of them is heterozygous or something. Tell us, was there a signal in one subtype versus the other?
Right. All three subtypes have bone mineral deficiency, although it is worse in 3s and the worst in 3s and 4s.
Yeah.
However, all three respond with improvement in bone mineral density, and all have response in bone. It is not a differentiation, but there is a differentiation in the type 3s and 4s have more deformed long bones, which may make a difference in how well they can heal.
Yeah.
You cannot change the structure of a bone. Just laying more bone on a weird curved bone.
Yeah.
Is not going to solve the structural problem that exists. That's the difference. In ORBIT, it turned out we had twice many 3s, the most severe ones.
Yeah.
In the setrusumab group, and it was type 4s in the other. That was an oddity. We did not expect that was probably hurt the study to some degree. We thought the study was large enough not to have to worry about it. That was one difference. All the groups types respond. In the OI type 1, they have a deficiency of collagen. They're not heterozygous, but they have a deficiency of collagen.
Yeah.
Type 3s and 4s, they have an abnormal collagen.
Right.
Not as, no, but abnormal. The normal collagen disrupts the cells. Formation of collagen also disrupts cell biology. The thing is people felt is that the collagen was causing the bone to be weak directly, like the structure of the collagen. The truth is that whether it's deficiency or structure of the collagen, there's an impact on bone regulation. What that means is the cells, the bones are resorbing their bone more and making less bone. The net effect is that you have very severe bone mineral density deficiency, less bone. While there may be a structural effect of the bone strength, they don't have enough bone.
The reason that's important is that setrusumab is going to make more bone, and therefore, in animal models with mutant collagen, and you make more bone, that you can normalize bone mineral density, and you actually get normal bone strength, even with an abnormal collagen. Okay? The truth is the bone regulation effect of the disease is more of the problem than it is the weakness of the collagen fiber.
That helps a lot. It seems like it works across different subtypes, and we'll see what the FDA says. I mean, lay out some scenario A, B, and C for us.
Sure.
It could either, they say, "Okay, submit based on existing data. It's high unmet need. Nothing's available, and do a confirmatory trial, or do a prospective trial and have that enrolled to a certain level, and we'll take a look at it, or just do a complete placebo control trial all over again with the learnings from Orbit and Cosmic.
Yeah, those are the range of options. We think we have a lot of data in hand if you focus on BMD. The BMD has not been accepted as a predictive biomarker by FDA for OI. But it has been accepted as a validated surrogate marker for osteoporosis.
Sure.
Now, the truth is both programs are, both types of the osteoporosis and osteogenesis imperfecta are different. They both have the common ground of BMD deficiency. So if one validated, you think it should be accepted. Right now, it's not, right? So that's part of what the discussion would be, is how predictive is BMD in OI. But it's right now not accepted as surrogate. The focus has been on fractures. So it's hard for us to pick the scenarios, but you could have a new trial required, some prospective new trial. We have also crossover data from the existing patients being treated.
Yeah.
This other set of data, and this discussion about the endpoints and what is clinical benefit in OI. Is there certain bones only that have benefit, or is it a broader view of what constitutes clinical benefit? So these are some of the discussions we're having. I don't want to go into more detail because I don't think it's productive. The question that people ask is, well, should they assume another trial is being conducted? And if you did that, how does that affect your financials?
Yeah.
And what we've said is that in our budget for next year, we're already including the fact that another trial could be conducted. So if we do another trial, it is included already in the numbers. It doesn't impact our plan, all right? That already is built in. That was a built-in assumption. Now, is that trial prospective, or is it a confirmatory requirement? That would be a question. But I think people should not assume that that trial is post-marketing. I don't think you should assume that as base case right now. I don't want to set that expectation. I would say we probably have to have some trial data in order to get approved. However, we certainly are looking at the possibilities of trying to do something less than that.
I mean, a trial of Cosmic size and inclusion/exclusion could work, if you made the entry criteria a certain way, and in a high fracture rate background. Oh, okay. When.
Yeah. The Cosmic was only 69 patients, so it's certainly a larger Cosmic trial is a little easier to do.
Yeah.
The reason it's easier to do, the placebo-controlled trial, the difficulty was, and the reason why we had lower fracture severity, is the doctors don't want to put patients in a trial that could be one to two years and take them off their bisphosphonate, right? Because that means they're going to get worse. So they didn't put their sickest patients in, even though we told them to. They ended up telling us afterward, well, they didn't want to put the sickest ones in, which is what they needed to do. Because they do not want to put their kids on withdrawal from the treatment that does help them right now for two years, up to two years, right? That was a big hurt. That was a factor. If we do another trial, it would probably be more like a Cosmic-like trial.
Yeah.
Therefore, we could have higher fracture patients. We are doing a head-to-head against active, but that would be the type of design you could do, and would also be better for patients' standpoint that they are not placebo-controlled and therefore they are not being denied treatment. It is also a trial you could do more readily in the post-marketing setting too, right? Obviously, because no one is being denied treatment, right? There are many features why that makes more sense.
When do you think you will be able to provide an update from the FDA after all the back and forth?
Well, as soon as the FDA gives us the answer we want.
Yeah.
The FDA negotiation is First of all, they have been collaborative. They are interested in the indication.
Yeah.
The group that is there has been there a while. That group has been there also and worked with us on Crysvita.
The same people. They have not turned over, just to be clear, because a lot has turned over at the FDA, but not that group. This is good. They are people that know us, know what work we do, the quality of the work, and are having a professional and thoughtful discussion with us. This is good. We want to try to move the field forward, and I just cannot tell you a predictive number. I know people want an answer immediately, but we are trying to move the field forward and change how we look at this disease. I think we are making progress. We have had meetings, there may be others. The idea that you do one meeting and everything is solved, that is a very simplest way of way reg works. Usually, it is more involved. FAYUVI on heparan sulfate was over a two-year period.
I do not say we are going to take two years. I am just saying it is kind of what can be at times.
Yeah.
Now, the FDA is a lot more stable than it has been, which is good. I think that the senior team there is very angled toward trying to help rare disease programs. That is the rare disease framework. They are talking about it. They want to, and we have connections to them. We think there is a good discussion to be had here on, here is a good example of a situation that I think could benefit, and in fact, probably needs to benefit from FDA thoughtfulness on how to approve a product for a rare disease like OI.
I mean, the head of CBER has turned over. Does that make a difference for you guys?
Well, because of Kyle.
The prior CBER head wanted a placebo for a lot of other things.
The new people, I think, are very rational and thoughtful. They're respectful reviewers, but also willing to engage. I think they actually have the right attitude and approach, and we're pleased to work with them. We did with FAYUVI and GENGLYCOS.
Yeah.
Both programs with the CBER head. CDER head, we know less about, but I think the team there has been more stable than the CBER team, which has turned over a lot. Look, I think we're encouraged by where the FDA is going. I think they're going the right way. Things are stabilizing. They're starting to fill in. I would say there's professional rational thinking going on, so that's good.
Yeah. We can go over a few more minutes. We have to talk about DTX401 for OTC. You already reported.
DTX301.
Oh, sorry. Oh, 401's approved.
Yes.
Yeah, sorry. DTX301 for OTC. You already reported very strong data from the blind portion of data, study phase III Enh3ance trial. What are you trying to achieve from the open label portion?
Yeah, so the blinded portion is really the important one. That showed excellent ammonia control, but more importantly than just ammonia control.
Yeah.
It talked about their brains getting clearer. The PGI-C, the Global Impression scales scores, showed 89% plus two, plus three. That means much better or very much better. 75% were plus three, that is very much better, versus 0% placebo. Even though these patients were stably on meds for OTC, standard of care, they felt much better. That is what the difference in having a gene therapy is that they get the actual enzyme and they control ammonia tightly.
That is what is important. What I would say to you is that really should be approvable, that alone. What we are looking at in the open label session is the ability to remove the current care and have the patient still be sustained. The challenge removing care is that patients are reluctant to remove care, like drugs, because that has been their security blanket.
Plus, a lot of them are not used to eating protein. To move quickly off it completely is a big faith. A lot of these late-onset types, by the way, were discovered they hadn't been doing any diet or drugs, and they're 12 years old, let's say, and they have a cold, and they end up in the ICU under coma. They have events. It's not like they get a little sick. They'll end up in the ICU and could die. If you're telling them, "Yeah, why don't you take away these security blanket drugs that have saved you?
Yeah, and trust that everything's going to be fine, it takes a little time. Doing it in a blinded phase, which FDA asked for, was not possible. What we're looking for is to see if we can get a fraction of the patient off their drugs and diet completely, and we'll see. But there is a sociologic aspect to this, which is getting people comfortable that they can go naked without any of these things. It's not like you know instantly if something's wrong. You may be fine and then have a crash. That's why they're afraid of it. But we're working through it. We expect to be able to have that by 64 weeks, need to get a certain fraction of patients off the drugs diet.
But I would say to you, the data we have on hand show the drug is valuable and should get approved. Ammonia is already accepted, in fact, a validated endpoint for FDA for approval. We've shown on average, we improved to normal range, but even the sickest patients got to normal range. We think that shows you that we can control ammonia far better than you can with current standard of care.
I'm looking forward to this getting approved because based on our conversations with doctors at these genetic medicine conferences, I mean, this seems like a much bigger TAM, relatively speaking, and much more patients are, how do you say this? More like FAYUVI, like unmet need is much more.
Sure.
Greater. That's great.
One of the really interesting things, though, is some of those TPs will think they were fine, even the ones in our study.
Yeah.
Then they find out what it is to have really good ammonia control.
Exactly.
They say, "I'm way better." You said you were fine, now you're way better, because they didn't even know what fine was. They don't know that what we feel like when your brain's clear. They have never had that before, so they don't know what feeling good feels like. After, they go, "I'm really feeling clear. My brain" They don't ever have that feeling. It's kind of exciting when they realize, "I wasn't fine. Now I'm fine." Okay. If you don't know, and you've been sick your whole life, it's hard to know. That's why the PGI-C data is so compelling, so dramatically better, when everyone said they were fine. I had people tell me, "Well, they're fine. They said so. The doctor said so." Then why are they still feeling so much better?
It's one of the things we learn in rare, when you're chronically ill, you don't know what good is until you get it.
I mean, I could go on and on, but I think we're out of time. Emil and Howard, thank you so much for your time, and we'll be watching your progress very closely.
Thank you.
Thanks, Joon Lee.
Thank you.